Advertisement

Test Approved to Help Determine Cause of Membranous Glomerulonephritis — Physician’s First Watch

Medical News |
June 2, 2014

Test Approved to Help Determine Cause of Membranous Glomerulonephritis

By Kelly Young

Edited by Susan Sadoughi, MD , and Jaye Elizabeth Hefner, MD

The FDA has approved the Euroimmun Anti-PLA2R IFA blood test to determine whether a patient's membranous glomerulonephritis (MGN) is autoimmune or related to another cause, like infection. About 85% of MGNs are considered primary (i.e., autoimmune) versus secondary (i.e., related to infections or tumors).

The test detects an antibody specific to primary MGN. In a study of 560 blood samples of patients with primary MGN and other kidney disorders, the assay accurately detected primary MGN 77% of the time and gave false-positive results less than 1% of the time.

The FDA notes that the test should not be the sole method used to make a diagnosis of primary MGN. Symptoms and other laboratory tests should also be taken into account. A kidney biopsy is required for confirmation.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement